Table 2 Genotype and change in Hb. Data are expressed as median (range)

From: Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial

Genotype

Placebo

Thalidomide

P

n

Hbd85-Hbd0 (g/L)

n

Hbd85–Hbd0 (g/L)

All patients

50

−5.5 (−10.5, 2)

49

14 (2.5, 37.5)

0.000

β0/β0

19

−7 (−10, 2)

9

5 (−2.5, 14.5)

0.047

β0/non-β0

25

−5 (−13.5, 0.5)

34

20 (3.8, 40.3)

0.000

non-β0/non-β0

6

−2.5 (−9.8, 13)

6

18 (−6.8, 41)

0.187

  1. Hbd85 Hb level of day 85 (after treatment with thalidomide for 12 weeks), Hbd0 Hb level of day 0 (baseline level). P values were determined by Mann–Whitney U test
Back to article page